Prospective Phase III validation for EndoPredict – Read more

Comparison of prognostic ability of EndoPredict® Breast Cancer Prognostic
Test and Oncotype DX®

Download the clinical summary

Decisions on the use of adjuvant chemotherapy in ER positive, HER2 negative primary breast cancer are guided by the risk of distant recurrence. EndoPredict provides prognostic information from a molecular signature combined with tumor size and nodal status (EPclin Risk Score). Oncotype DX® provides prognostic information only from a molecular signature (Recurrence Score – RS).

This study validated the prognostic value of EndoPredict and compared the prognostic ability of EndoPredict with Oncotype DX®.

Fill out the form below to download your free copy of the comparison clinical summary and learn more about this key study.

Premenopausal clinical summary front cover image